Next month, top scientists, researchers, and industry professionals from around the world will gather for a landmark conference, iPSC Modelling in Neuromuscular Disorders (iMND), that promises to reshape the future of neuromuscular disorder research. The focus of the event is human induced pluripotent stem cell (hiPSC) technology, a revolutionary tool that is transforming the way scientists model and study these devastating conditions.
hiPSC technology: a game changer in neuromuscular disorder research
Neuromuscular disorders, such as amyotrophic lateral sclerosis (ALS) and muscular dystrophy, remain among the most complex diseases to understand and treat. Historically, researchers have struggled to model these disorders accurately due to the limitations of animal models, which cannot fully replicate the complexity of human disease. Moreover, the inaccessibility of patients' neurons has made direct study of affected cells nearly impossible.
This is where hiPSC technology steps in. By reprogramming skin cells from patients into pluripotent stem cells, researchers can now generate any cell type involved in the disease, including motor neurons and muscle cells. These cells can be used to create highly relevant, humanized models of neuromuscular disorders. Through both 2D and, more recently, 3D hiPSC models, scientists can now better mimic the human in vivo environment, allowing for more accurate studies of disease mechanisms and the development of potential therapeutic strategies.
Challenges and collaboration: the path forward
Despite significant advancements, challenges remain. “There’s still much to be achieved,” said Adriana Correia, one of the conference organizers who works at Ludo Van Den Bosch’s lab. “Sharing knowledge, exchanging ideas, and debating methodologies is essential to accelerating progress in the field. This meeting aims to do just that—bring together academia, industry, and leading researchers to discuss the potential, limitations, and reproducibility of hiPSC models.”
Short talks, significant impact
With a program packed with talks, attendees will have the opportunity to hear from a diverse range of experts, each distilling their findings into essential insights. They will also be able to present their research during the poster sessions or when selected for a short talk slot. If you're interested, make sure to submit your research before the abstract deadline of 15 September.
Adriana added: “As a PhD student studying ALS using hiPSCs, I’m excited about the opportunity to meet researchers I have long admired. This meeting offers a unique chance to connect with fellow students, researchers, and industry professionals. I hope to brainstorm ideas, share insights, and maybe even spark new collaborations.”
Looking ahead: collaboration as the key to progress
The conference will provide a platform for knowledge-sharing and serve as a springboard for future discoveries and partnerships. "Collaboration is key to advancing science," Adriana emphasized. "This event is about fostering those connections that can lead to breakthroughs."
The iMND meeting is set to be an essential milestone for anyone working on or interested in hiPSC technology and neuromuscular disorders. "We encourage all researchers in this field, or anyone curious about starting with hiPSCs, to join us here in Leuven," Adriana concluded.
This conference marks a pivotal step forward in the search for better understanding and treatments for neuromuscular disorders, offering hope to patients worldwide.
Upcoming deadlines
- 15 September: Abstract deadline
- 25 September: Early Bird deadline
Find out more on the conference website:
